Gilead Sciences【GILD】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

87.75

買値

87.55

売値

87.98

出来高

0.00 日の範囲 0.00

62.07 52 週間の範囲 98.90

時価総額

109.248B

前日終値

87.75

始値

時刻

87.7

最終取引時間

18:15:15

財務取引量

VWAP

平均取引量 (3 か月)

6,789,211

発行済株式数

1,244,992,081

配当利回り

3.51%

PER

19.28

1 株当たり利益 (EPS)

4.55

歳入

27.12B

純利益

5.67B

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. 詳細を表示

セクター

Biological Pds,ex Diagnstics

業界

Biological Pds,ex Diagnstics

ウェブサイト

www.gilead.com

本社

Wilmington, Delaware, USA

設立

Gilead Sciences Inc is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker GILD. The last closing price for Gilead Sciences was US$87.75. Over the last year, Gilead Sciences shares have traded in a share price range of US$ 62.07 to US$ 98.90.

Gilead Sciences currently has 1,244,992,081 shares in issue. The market capitalisation of Gilead Sciences is US$109.25 billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 19.28.

全体の流れ

ブルリッシュ

ネットプレミアム

1M

Calls / Puts

325.00%

買い / 売り

54.55%

OTM / ITM

142.86%

Sweeps比率

0.00%

Form 424B5 - Prospectus [Rule 424(b)(5)]

Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

– New Findings Demonstrate 81% of Participants Achieve Durable Biochemical Response by Month 30 with Livdelzi – – Nearly Half of Participants with Primary Biliary Cholangitis (PBC) Achieve...

Gilead Prices $3.5 Billion of Senior Unsecured Notes

Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior...

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Form 424B5 - Prospectus [Rule 424(b)(5)]

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

– Newly Presented Results, to be Published in The New England Journal of Medicine, Include Adherence and Pharmacokinetics Data; Data Underscore High Efficacy and Safety Profile of Lenacapavir...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

– Four-Year Outcomes from the BICSTaR Study Further Demonstrate the Long-Term Efficacy and Safety Profile of Biktarvy®, Providing Insights for HIV Clinical Care – – New Data on HIV Treatment...

Gilead Sciences to Present at Upcoming Investor Engagements

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthcare Conference on Wednesday, November 20...

Form 4 - Statement of changes in beneficial ownership of securities

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-6.38	-6.77786040582	94.13	94.17	86.08	9480743	89.9143244	CS
4	-0.4582	-0.519452839985	88.2082	98.9	86.08	7535089	91.29359577	CS
12	10.29	13.2842757552	77.46	98.9	77.23	6789211	86.19104531	CS
26	20.03	29.5776727702	67.72	98.9	62.07	6840584	77.41410015	CS
52	12.52	16.642296956	75.23	98.9	62.07	6968431	75.97474904	CS
156	19.05	27.7292576419	68.7	98.9	57.165	7173188	73.01344183	CS
260	22.97	35.4584748379	64.78	98.9	56.56	8405259	71.27416142	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.31 (90.53%)	16.53M
DBGIDigital Brands Group Inc	US$ 0.1799 (54.29%)	10.56M
KITTNauticus Robotics Inc	US$ 1.26 (38.43%)	2.65M
BSVOEA Bridgeway Omni Small Cap Value ETF	US$ 30.00 (31.82%)	5
HOTHHoth Therapeutics Inc	US$ 1.05 (28.36%)	990.75k
PRFXPainReform Ltd	US$ 1.08 (-22.86%)	224.65k
CNXNPC Connection Inc	US$ 56.30 (-19.44%)	200
QTTBQ32 Bio Inc	US$ 23.50 (-19.22%)	3
CMPRCimpress PLC	US$ 63.70 (-17.30%)	7
IBCPIndependent Bank Corporation	US$ 31.53 (-15.45%)	1
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.31 (90.53%)	16.55M
DBGIDigital Brands Group Inc	US$ 0.18 (54.37%)	10.56M
KITTNauticus Robotics Inc	US$ 1.27 (39.53%)	2.65M
ELABElevai Labs Inc	US$ 0.0211 (-0.94%)	1.85M
HOTHHoth Therapeutics Inc	US$ 1.05 (28.36%)	990.78k